文献速递泌尿生殖介入US

超声引导经皮微波消融治疗临床T1期肾细胞癌:多中心10年肿瘤学结局

A multicenter 10-year oncologic outcome of ultrasound-guided percutaneous microwave ablation of clinical T1 renal cell carcinoma: will it stand the test of time?
PubMed 文献 · Eur Radiol · 2021-06-30

这项五中心回顾性研究纳入323例T1N0M0肾细胞癌患者的371个肿瘤,评估超声引导经皮微波消融的长期疗效。技术有效率97.0%,cT1a患者10年肿瘤局部进展率1.9%、癌症特异性生存率87.4%,cT1b患者5年局部进展率11.3%。结论认为该治疗对cT1a(即使位置危险)可靠,对cT1b也有前景。

要点

  • 42.6%肿瘤邻近集合系统或肠管,技术有效率仍达97.0%,注意评估危险位置。
  • cT1b肿瘤5年局部进展率11.3%,疗效尚可但需更严格随访。

关键影像表现/征象

  • 共371个肿瘤,平均直径2.9 cm±1.2,42.6%位于集合系统/肠管邻近区域。
  • 技术有效率97.0%(360/371个肿瘤)。
  • cT1a患者中位随访66.0个月(IQR 58.4-73.6),10年局部肿瘤进展率1.9%。
  • cT1b患者中位随访30.4个月(IQR 17.7-44.8),5年局部肿瘤进展率11.3%。

诊断标准与关键数值

  • cT1a患者10年癌症特异性生存率87.4%、无病生存率71.8%、总生存率67.5%。
  • cT1b患者5年癌症特异性生存率91.4%、无病生存率69.1%、总生存率89.2%。
  • 主要并发症发生率cT1a 3.5%、cT1b 6.9%,两者无差异(p=0.28)。
  • 基于多变量模型建立临床风险分层系统预测DFS和CSS,c-index分别为0.78(95%CI 0.71-0.85)和0.77(95%CI 0.65-0.90)。

临床应用与阅片要点

  • 对于cT1a肾细胞癌,即使肿瘤邻近集合系统或肠管,超声引导微波消融仍可达到高技术有效率和良好长期局部控制。
  • cT1b肿瘤行微波消融后局部进展风险相对较高(5年11.3%),阅片随访时需更关注消融区边缘。
  • 可参考研究提出的风险分层系统(c-index 0.78/0.77)辅助预测无病生存和癌症特异性生存,但需外部验证。

局限性

  • 回顾性研究设计。
  • cT1b亚组随访时间较短(中位30.4个月),长期结局需进一步观察。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: We updated the experience on percutaneous microwave ablation for renal cell carcinoma with five-center data and long-term follow-up.

METHODS: This retrospective study reviewed the T1N0M0 renal cell carcinoma patients who underwent microwave ablation between April 2006 and December 2019. Clinicopathological and procedural data were collected. Technical effectiveness and complications were assessed, and the Kaplan-Meier method was used for cancer-specific survival, disease-free survival, overall survival, and local neoplastic process analyses.

RESULTS: A total of 323 consecutive patients (mean age, 62.9 years ± 14.0) with 371 biopsy-proved tumors (mean diameter, 2.9 cm ± 1.2) were enrolled, and 42.6% of the tumors were located adjacent to collecting system/bowel and technical effectiveness was achieved in 360 (97.0%) tumors. For 275 cT1a patients, during median follow-up time of 66.0 months (IQR, 58.4-73.6), 10-year local neoplastic processes, cancer-specific survival, disease-free survival, and overall survival rates were 1.9%, 87.4%, 71.8, and 67.5%, respectively. For 48 cT1b patients, during the median follow-up time of 30.4 months (IQR, 17.7-44.8), 5-year local tumor progression, cancer-specific survival, disease-free survival, and overall survival rates were 11.3%, 91.4%, 69.1, and 89.2%, respectively. Major complications showed no differences between cT1a (3.5%) and cT1b (6.9%) patients (p = 0.28). A clinical risk stratification system was developed based on multivariable model to predict DFS and CSS with c-indexes of 0.78 (95% CI: 0.71-0.85) and 0.77 (95% CI: 0.65-0.90), respectively.

CONCLUSIONS: With matured follow-up at five institutions, ultrasound-guided percutaneous microwave ablation is a reliable treatment option for cT1a renal cell carcinoma even in dangerous location and appears to be promising for cT1b tumors.

KEY POINTS: • To our knowledge, this is the first multicenter cohort of long-term oncologic outcomes with percutaneous MWA of cT1 RCC. • The predicting model we developed is accurate to predict the long-term DFS and CSS, which can help to provide a better MWA prognostication over routinely available clinical information. • The available evidence shows that microwave ablation of clinical stage T1 RCC is safe and reliable with promising long-term oncologic outcomes, especially for cT1a RCC with excellent 10-year results.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Yu J, Wang H, Cheng ZG, et al. A multicenter 10-year oncologic outcome of ultrasound-guided percutaneous microwave ablation of clinical T1 renal cell carcinoma: will it stand the test of time? Eur Radiol. 2021. PMID: 34195888. doi:10.1007/s00330-021-07900-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。